TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation

Trial Profile

TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Lapatinib (Primary) ; Cisplatin
  • Indications Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer
  • Focus Therapeutic Use
  • Acronyms TRYHARD
  • Most Recent Events

    • 19 Jul 2017 Planned End Date changed from 1 Nov 2018 to 31 Mar 2023.
    • 19 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 31 Mar 2020.
    • 19 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top